Traders should monitor the AAD presentation on March 28 for detailed efficacy data, which could drive near-term upside. The Breakthrough Therapy Designation de-risks development and increases probability of approval, supporting long-term valuation upside if Phase 3 confirms results.
Price Chart
Executive Summary
Biogen announced upcoming presentation of late-breaking Phase 2 (Part A) results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus (CLE) at the 2026 American Academy of Dermatology meeting. The data supported the FDA's recent Breakthrough Therapy Designation for litifilimab, a potential first-in-class monoclonal antibody targeting BDCA2, highlighting its safety and efficacy in a disease with no approved targeted therapies since the 1950s.
Key Facts
- Litifilimab received FDA Breakthrough Therapy Designation for CLE based on Phase 2 LILAC and AMETHYST Part A results.
- Late-breaking 24-week Phase 2 AMETHYST Part A data will be presented at AAD 2026, showing efficacy and safety in CLE.
- Phase 3 part of AMETHYST is ongoing with data expected in 2027.
- Litifilimab is a first-in-class anti-BDCA2 monoclonal antibody discovered in-house at Biogen.
- CLE has no approved targeted therapies; current standard of care dates back to the 1950s.
Financial Impact
High commercial potential given unmet need in CLE and Breakthrough Therapy status, though no revenue impact until 2027 at earliest.
Risk Factors
- Phase 3 data may not replicate Phase 2 results.
- Regulatory approval is not guaranteed despite Breakthrough status.
- Commercial uptake could be limited by competition or pricing challenges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258886 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 28d ago | Press Release | $220.83 $217.36 | ▼ −1.57% | ▼ −0.36% | $219.88 (−0.43%) |
Sep 3, 2026 29d ago | Press Release | $224.51 $217.15 | ▼ −3.28% | ▼ −2.13% | $219.88 (−2.06%) |
Aug 6, 2026 8w ago | Press Release | $207.94 $209.83 | ▲ +0.91% | ▲ +0.51% | $219.88 (+5.74%) |
Jul 14, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Jun 17, 2026 15w ago | Press Release | $196.58 $201.96 | ▲ +2.74% | ▲ +4.40% | $219.88 (+11.85%) |
Jun 8, 2026 16w ago | ANALYST-UPGRADE | $192.62 $198.64 | ▲ +3.13% | ▲ +1.01% | $219.88 (+14.15%) |
Jun 4, 2026 17w ago | Press Release | $195.82 $199.96 | ▲ +2.12% | ▲ +4.67% | $219.88 (+12.29%) |
Jun 1, 2026 17w ago | Press Release | $192.22 $195.34 | ▲ +1.63% | ▲ +4.38% | $219.88 (+14.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access